Download PDF
Thromb Haemost 1996; 75(02): 318-325
DOI: 10.1055/s-0038-1650268
Original Article
Schattauer GmbH Stuttgart

Induction of Human Factor VIII Inhibitors in Rats by Immunization with Human Recombinant Factor VIII: a Small Animal Model for Humans with High Responder Inhibitor Phenotype

M A Jarvis
1   The Department of Internal Medicine, University of California at Davis, Davis, CA, USA
3   The Department of Pediatrics, University of California at Davis, Davis, CA, USA
,
L G Levin
4   The Departments of Pathology and Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA
,
J A Harrison
3   The Department of Pediatrics, University of California at Davis, Davis, CA, USA
,
D J DePianto
3   The Department of Pediatrics, University of California at Davis, Davis, CA, USA
,
C M Suzuki
2   The Department of Obstetrics and Gynecology, University of California at Davis, Davis, CA, USA
,
C L Ziaja
3   The Department of Pediatrics, University of California at Davis, Davis, CA, USA
,
J E Brown
5   The Department of Bayer, Pharmaceutical Division, Berkeley, CA, USA
,
K W Jolly
3   The Department of Pediatrics, University of California at Davis, Davis, CA, USA
,
H M Reisner
4   The Departments of Pathology and Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA
,
C F Abidgaard
3   The Department of Pediatrics, University of California at Davis, Davis, CA, USA
,
J S Powell
1   The Department of Internal Medicine, University of California at Davis, Davis, CA, USA
› Author Affiliations
Further Information

Publication History

Received: 14 July 1995

Accepted after revision25 October 1995

Publication Date:
27 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Hemophilia A is a clotting disorder that is due to reduced or absent coagulation factor VIII (FVIII) activity. In approximately 25% of people with severe hemophilia A, standard treatment with intravenous plasma-derived or recombinant FVIII (rFVIII) induces anti-FVIII antibodies that inhibit FVIII activity (inhibitors). We describe the development of a rat model to study the formation of inhibitors. Immunization of rats with human rFVIII in adjuvant induced an anti-human rFVIII antibody response characteristic of an anti-FVIII inhibitor response in hemophilia A patients. The rats exhibited a rapid, polyclonal secondary antibody response to human rFVIII. These antibodies were reactive against epitopes located in the heavy and light chains. All the rFVIII-immunized rats developed antibodies against the FVIII C2 domain, a region of major reactivity in hemophilia A patients with inhibitors. Furthermore, competition ELISAs demonstrated that rat and human anti-FVIII antibodies recognized identical or overlapping epitopes of the FVIII molecule. The rat anti-FVIII antibodies also functioned as human FVIII inhibitors with titers ranging from 120 to 2048 Bethesda Units (B.U.). We propose that this rat model may be useful to investigate immune responses to FVIII and may lead to better therapies for FVIII inhibitors.

 

  • References

  • 1 Foster P, Zimmerman T. Factor VIII structure and function. Blood Reviews 1989; 3: 180-191
    CrossrefPubMedGoogle Scholar
  • 2 Fulcher CA. Immunochemistry of Factor VIII:C inhibitor antibodies. Am J Med 1991; 91 (05) 6S-8S
    PubMedGoogle Scholar
  • 3 Hoyer LW, Scandella D. Factor VIII inhibitors: Structure and function in autoantibody and hemophilia patients. Semin Hematol 1994; 31 (Suppl. 04) Suppl 1-5
    PubMedGoogle Scholar
  • 4 Lollar P. Structure and function of Factor VIII. In: Inhibitors to Coagulation Factors Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White GC. eds Plenum, New York, NY: 1995: 3-18
  • 5 McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. Hemophilia Study Group. The natural history of factor VIII:C inhibitors in patients with hemophilia A: A national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988 71. 344-348
    PubMedGoogle Scholar
  • 6 Allain J-P, Frommel D. Antibodies to factor VIII. V. Patterns of Immune response to factor VIII in Hemophilia A. Blood 1976; 47: 973-982
    PubMedGoogle Scholar
  • 7 Bloom AL. Management of FVIII inhibitors: Evolution and current status. Haemostasis 1992; 22: 268-275
    PubMedGoogle Scholar
  • 8 Kessler CM. Factor VIII inhibitors: An algorithmic approach to treatment. Semin Hematol 1994; 31 (Suppl. 04) Suppl 33-36
    PubMedGoogle Scholar
  • 9 Mariani G, Scheibel E, Nogao T, Kasper CK, Ewing NP, Mauser-Bunscho-ten E, Ghirardini A, Bellocco R, Brackman HH. Immunetolerance as treatment of alloantibodies to factor VIII in hemophilia. The International Registry of Immunetolerance Protocols. Semin Hematol 1994; 31 (Suppl. 04) Suppl 62-64
    PubMedGoogle Scholar
  • 10 Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia: Principal results from the International Registry. Report of the Factor VIII and IX Subcommittee. Thromb Haemost 1994; 72: 155-158
    PubMedGoogle Scholar
  • 11 Ehrenforth S, Kreuz W, Funk M, Auerswald G, Scharrer I. Variables that might affect the outcome of immune tolerance therapy in haemophilia with factor VIII inhibitors. Thromb Haemost 1994; 72: 784-785
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Tinlin S, Webster S, Giles AR. The development of homologous (canine/anti-canine) antibodies in dogs with haemophilia A (factor VIII deficiency): A ten-year longitudinal study. Thromb Haemost 1993; 69: 21-24
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Giles AR. Functional, biochemical and morphological evaluations of experimental hemophilia therapies in animal models. Semin Hematol 1994; 31 (Suppl. 04) Suppl 56-59
    PubMedGoogle Scholar
  • 14 Finney M. Molecular cloning of PCR products. Alternate Protocol: Generation of Half-Sites. In: Current Protocols in Molecular Biology, vol 2 Coen DM. ed Wiley and Sons; New York, NY: 1994: 15.7.3-15.8.8
  • 15 Laemmli UK. Cleavage of structure protein during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
    CrossrefPubMedGoogle Scholar
  • 16 Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J, Fratan-toni J, Green D, Hampton J, Hilgartner M, Levine P, Lazerson J, McMillan C, Penner J, Shapiro S, Shulman NR. Proceedings: A more uniform measurement of factor VIII inhibitors. Thrombos Diathes Haemorr 1975; 35: 869-872
    PubMedGoogle Scholar
  • 17 Berzofsky JA, Schechter AN, Kon H. Does Freund’s adjuvant denature protein antigens? EPR studies of emulsified hemoglobin. J Immunology 1976; 115: 270-272
    PubMedGoogle Scholar
  • 18 Smith JA, Hurrell JGR, Leach SJ. Conformational integrity of myoglobin after immunization with Freund’s adjuvant. J Immunol 1977; 118: 226-228
    PubMedGoogle Scholar
  • 19 Antonarakis SE, Kazazian HH, Gitshier J, Hutter P, de Moerloose P, Morris M. Molecular etiology of Factor VIII deficiency in Hemophilia A. In: Inhibitors to Coagulation Factors Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White GC. eds Plenum, New York, NY: 1995: 19-34
  • 20 Reisner HM, Clark A, Levin L. Immunogenetics of the Human Immune Response to Factor VIII. In: Inhibitors to Coagulation Factors Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White GC. eds Plenum, New York, NY; 1995: 65-78
  • 21 Gilles JGG, Amout J, Vermylen J, Saint-Remy J-MR. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 1993; 82: 2452-2461
    PubMedGoogle Scholar
  • 22 Fulcher CA, De Graaf Mahoney S, Zimmerman TS. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 1987; 69: 1475-1480
    PubMedGoogle Scholar
  • 23 Scandella D, Mattingly M, De Graaf S, Fulcher CA. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood 1989; 74: 1618-1626
    PubMedGoogle Scholar
  • 24 Scandella D, Mahoney De Graaf S, Mattingly M, Roeder D, Timmons L, Fulcher CA. Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli. Proc Natl Acad Sci USA 1988; 85: 6152-6156
    CrossrefPubMedGoogle Scholar
  • 25 Weigle WO. The immune response of rabbits tolerant to bovine serum albumin to the injection of other heterologous serum albumins. J Immunol 1961; 114: 111-122
    PubMedGoogle Scholar
  • 26 Zamvil SS, Steinman L. The Tlymphocyte in experimental allergic encephalomyelitis. Ann Rev Immunol 1990; 8: 579-621
    CrossrefPubMedGoogle Scholar
  • 27 Wacker WB, Donoso LA, Kalsow CM, Yankeelov Jr JA, Organisciak DT. Isolation, characterization, and localization of a soluble uveitopathogenic antigen from bovine retina. J Immunol 1977; 119: 1949-1958
    PubMedGoogle Scholar
  • 28 Pearson CM. Experimental joint disease: Observations on adjuvant induced arthritis. J Chron Dis 1963; 16: 863-874
    CrossrefPubMedGoogle Scholar
  • 29 Pittman DD, Alderman EM, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ. Biochemical, immunological and in vivo functional characterization of B-domain-deleted Factor VIII. Blood 1993; 81: 2925-2935
    PubMedGoogle Scholar